ACAD AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
ACAD Current Performance
3.18%
Acadia pharmaceuticals, inc.
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ACAD
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
NMRA | Neumora therapeutics inc | - | 4 | 5 | 2 | 1 | |
ATHA | Athira pharma inc | 1 | 4 | 2 | 1 | 1 | |
CCCC | C4 therapeutics inc | 3 | 3 | 4 | 3 | 1 | |
MORF | Morphic holding inc | 3 | 5 | 2 | 2 | 1 | |
RXRX | Recursion pharmaceuticals inc | 2 | 2 | 4 | 3 | 1 |
- NMRA Neumora therapeutics incValue -Trend 4Swing Trading 5Whale Interest 2Dividend 1See more
ACAD Profile
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.